Purple Biotech (PPBT) Income from Non-Controlling Interests (2017 - 2026)
Purple Biotech (PPBT) posted quarterly Income from Non-Controlling Interests of $3000.0 for Q1 2026, little changed year-over-year from $3000.0 in Q1 2025, and down 96.91% quarter-over-quarter from $97000.0 in Q4 2025.
Purple Biotech (PPBT) Income from Non-Controlling Interests (2017 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Income from Non-Controlling Interests for 10 consecutive years, with $3000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Non-Controlling Interests changed 0.0% year-over-year to $3000.0; the TTM figure through Mar 2026 stood at $106000.0 (up 360.87% YoY), while the FY2025 annual figure was $739000.0, down 70.96% from the prior year.
- Income from Non-Controlling Interests eased to $3000.0 in Q1 2026 per PPBT's latest filing, from $97000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $97000.0 in Q4 2025 and bottomed at $2000.0 in Q3 2025.
- Historically, Income from Non-Controlling Interests has averaged $19823.5 across 5 years, with a median of $19000.0 in 2022.
- On a YoY basis, Income from Non-Controlling Interests climbed as much as 1840.0% in 2025 and fell as far as 84.21% in 2025.
- Purple Biotech's Income from Non-Controlling Interests stood at $32000.0 in 2022, then slipped by 3.12% to $31000.0 in 2023, then slumped by 83.87% to $5000.0 in 2024, then surged by 1840.0% to $97000.0 in 2025, then tumbled by 96.91% to $3000.0 in 2026.
- Business Quant data shows PPBT's Income from Non-Controlling Interests at $3000.0 in Q1 2026, $97000.0 in Q4 2025, and $2000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | Purple Biotech | 130.35 | 130.35 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3,000.00 |
| Dec 31, 2025 | 97,000.00 |
| Sep 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 4,000.00 |
| Mar 31, 2025 | 3,000.00 |
| Dec 31, 2024 | 5,000.00 |
| Sep 30, 2024 | 5,000.00 |
| Jun 30, 2024 | 10,000.00 |
| Mar 31, 2024 | 19,000.00 |
| Dec 31, 2023 | 31,000.00 |
| Sep 30, 2023 | 19,000.00 |
| Jun 30, 2023 | 22,000.00 |
| Mar 31, 2023 | 25,000.00 |
| Dec 31, 2022 | 32,000.00 |
| Sep 30, 2022 | 25,000.00 |
| Jun 30, 2022 | 16,000.00 |
| Mar 31, 2022 | 19,000.00 |
| Dec 31, 2021 | 46,000.00 |
| Sep 30, 2021 | 12,000.00 |
| Jun 30, 2021 | 16,000.00 |